These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28442998)

  • 1. Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms.
    Tenenbaum L; Humbert-Claude M
    Front Neuroanat; 2017; 11():29. PubMed ID: 28442998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
    Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
    Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDNF family ligand dependent STAT3 activation is mediated by specific alternatively spliced isoforms of GFRα2 and RET.
    Zhou L; Too HP
    Biochim Biophys Acta; 2013 Dec; 1833(12):2789-2802. PubMed ID: 23872421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
    Herzog CD; Brown L; Kruegel BR; Wilson A; Tansey MG; Gage FH; Johnson EM; Bartus RT
    Neurobiol Dis; 2013 Oct; 58():38-48. PubMed ID: 23631873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of RET and GDNF family receptor, GFR-α1, between striatum and substantia nigra following nigrostriatal lesion: a case for diminished GDNF-signaling.
    Kasanga EA; Han Y; Navarrete W; McManus R; Shifflet MK; Parry C; Barahona A; Manfredsson FP; Nejtek VA; Richardson JR; Salvatore MF
    bioRxiv; 2023 Mar; ():. PubMed ID: 36909534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term exposure to GDNF induces dephosphorylation of Ret, AKT, and ERK1/2, and is ineffective at protecting midbrain dopaminergic neurons in cellular models of Parkinson's disease.
    Mesa-Infante V; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Barroso-Chinea P
    Mol Cell Neurosci; 2022 Jan; 118():103684. PubMed ID: 34826608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF).
    Saarma M; Sariola H
    Microsc Res Tech; 1999 May 15-Jun 1; 45(4-5):292-302. PubMed ID: 10383122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity in the crosstalk of TGFbeta/GDNF family members is determined by distinct GFR alpha receptors.
    Peterziel H; Paech T; Strelau J; Unsicker K; Krieglstein K
    J Neurochem; 2007 Dec; 103(6):2491-504. PubMed ID: 17953664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.
    Fjord-Larsen L; Johansen JL; Kusk P; Tornøe J; Grønborg M; Rosenblad C; Wahlberg LU
    Exp Neurol; 2005 Sep; 195(1):49-60. PubMed ID: 15919076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GDNF Therapy: Can We Make It Work?
    Björklund A
    J Parkinsons Dis; 2021; 11(3):1019-1022. PubMed ID: 33935108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery.
    Chu Y; Kordower JH
    Mov Disord; 2023 Sep; 38(9):1728-1736. PubMed ID: 37544016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
    Mandel RJ; Snyder RO; Leff SE
    Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glial cell line-derived neurotrophic factor/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFR alpha-1, and GFR alpha-2.
    Hishiki T; Nimura Y; Isogai E; Kondo K; Ichimiya S; Nakamura Y; Ozaki T; Sakiyama S; Hirose M; Seki N; Takahashi H; Ohnuma N; Tanabe M; Nakagawara A
    Cancer Res; 1998 May; 58(10):2158-65. PubMed ID: 9605760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glial cell line-derived neurotrophic factor family ligands and their therapeutic potential].
    Sidorova YA; Saarma M
    Mol Biol (Mosk); 2016; 50(4):589-598. PubMed ID: 27668599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of glial cell line-derived neurotrophic factor induced intracellular activity by K-252b on dopaminergic neurons.
    Pong K; Xu RY; Beck KD; Zhang TJ; Louis JC
    J Neurochem; 1997 Sep; 69(3):986-94. PubMed ID: 9282920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy.
    Domanskyi A; Saarma M; Airavaara M
    Hum Gene Ther; 2015 Aug; 26(8):550-9. PubMed ID: 26176331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease.
    Dietz GP; Valbuena PC; Dietz B; Meuer K; Müeller P; Weishaupt JH; Bähr M
    Brain Res; 2006 Apr; 1082(1):61-6. PubMed ID: 16703672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion.
    McGrath J; Lintz E; Hoffer BJ; Gerhardt GA; Quintero EM; Granholm AC
    Cell Transplant; 2002; 11(3):215-27. PubMed ID: 12075987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Therapeutic Approach using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease.
    Tripathi RK; Goyal L; Singh S
    Curr Gene Ther; 2024; 24(4):278-291. PubMed ID: 38310455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.